Old Web
English
Sign In
Acemap
>
authorDetail
>
Daniel Thurley
Daniel Thurley
Hoffmann-La Roche
Medicine
Rituximab
Immunology
Refractory
Population
4
Papers
26
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A multi‐centre, single‐arm, open‐label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R‐ITP1000 study)
2014
British Journal of Haematology
Huyen Tran
Timothy A. Brighton
Andrew Grigg
Simon McRae
Joanna Dixon
Daniel Thurley
Maher K. Gandhi
Matt Truman
Paula Marlton
John Catalano
Show All
Source
Cite
Save
Citations (23)
A Multi-Centre, Single-Arm, Open-Label Study Evaluating the Safety and Efficacy of Fixed Dose Rituximab in Patients with Refractory, Relapsing or Chronic Idiopathic Thrombocytopenic Purpura (R-ITP1000 Study) and Exploring Rituximab Response with the FcGammaR3A Polymorphisms
2011
Blood
Huyen Tran
Jamie P. Nourse
Rod A. Lea
Timothy A. Brighton
Andrew Grigg
Simon McRae
Daniel Thurley
Maher K. Gandhi
John Catalano
Show All
Source
Cite
Save
Citations (0)
The MAXIMA Study: Safety of Rituximab (MabThera®) Maintenance Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma Who Have Responded to Induction Therapy.
2007
Blood
Michael K. Wenger
Robin Foà
Luca Arcaini
Andrej Vranovský
Valentina Ivanova
Van Hazel Guy
Sabira Kurtovic
Soledad Durán
Stephen McKechnie
Daniel Thurley
Show All
Source
Cite
Save
Citations (2)
A Phase IIIb Study of Rituximab Maintenance Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma Who Have Responded to Induction Therapy - MAXIMA-Protocol.
2006
Blood
Manfred Hensel
Mathias Witzens Harig
Peter Dreger
Anthony D. Ho
Daniel Thurley
Stephan Oertel
Show All
Source
Cite
Save
Citations (1)
1